Company

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Nona Biosciences announced on July 23, 2026 a strategic research collaboration with the Medical University...

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026

Private enterprises from Pakistan and China have signed nine pharmaceutical sector agreements valued at approximately...

Company Drug

AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial

Fineline Cube Jul 24, 2026

AstraZeneca plc (NYSE: AZN) announced that the European Union has granted marketing authorization for Etcamah...

Company Medical Device

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

Fineline Cube Jul 23, 2026

Shanghai MicroPort MedBot (Group) Co., Ltd. (HKG: 2252) issued a positive profit alert announcing its...

Company Drug

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

Fineline Cube Jul 23, 2026

CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the initiation of a Phase 2 clinical trial...

Company Drug

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Fineline Cube Jul 23, 2026

PegBio Co., Ltd. (HKG: 2565) announced the successful issuance of the first batch of commercial...

Company Drug

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

Fineline Cube Jul 23, 2026

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Limited (HKG:...

Company Medical Device

OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon

Fineline Cube Jul 23, 2026

OrbusNeich Medical Group Holdings Limited (HKG: 6929) announced the successful enrollment of the first patient...

Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026

Summit Therapeutics Inc. (NASDAQ: SMMT), in partnership with Akeso, Inc. (HKG: 9926), announced a strategic...

Company Drug

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Fineline Cube Jul 23, 2026

GlaxoSmithKline plc (GSK) (NYSE: GSK) announced on July 22, 2026 that the U.S. Food and...

Company Drug

Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer

Fineline Cube Jul 23, 2026

Pfizer Inc. (NYSE: PFE) announced on July 22, 2026 that the U.S. Food and Drug...

Company Drug

Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease

Fineline Cube Jul 23, 2026

Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced positive results from a Phase 2a...

Company Drug

Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China

Fineline Cube Jul 23, 2026

Haisco Pharmaceutical Group Co., Ltd. (SHE: 002653) announced that China’s National Medical Products Administration (NMPA)...

Company Drug

Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy

Fineline Cube Jul 23, 2026

Takeda Pharmaceutical Company Limited (TYO: 4502; NYSE: TAK) announced that China’s National Medical Products Administration...

Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026

Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607) announced a RMB 300 million (approximately...

Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026

TYK Medicines (HKG: 2410) and Qilu Pharmaceutical announced a comprehensive strategic partnership comprising three agreements:...

Company Drug

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Fineline Cube Jul 22, 2026

Youcare Pharmaceutical (SHA: 688658) announced that its investigational compound YKYY033 has received clinical trial approval...

Company Deals

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Fineline Cube Jul 22, 2026

Trinomab Biotechnology Co., Ltd. (SHA: 688806) officially listed on the Science and Technology Innovation Board...

Company Legal / IP

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market

Fineline Cube Jul 22, 2026

Novo Nordisk A/S (NYSE: NVO) announced it has filed a lawsuit against Eli Lilly and...

Company Drug

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

Fineline Cube Jul 22, 2026

Junshi Biosciences (HKG: 1877, SHA: 688180) announced that the National Medical Products Administration (NMPA) has...

Company

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

AstraZeneca’s Etcamah Wins EU Approval for ESR1-Mutated Breast Cancer – Next-Gen SERD Shows 56% Risk Reduction in Pivotal Trial

MicroPort MedBot Achieves First-Ever Semi-Annual Profit on 200-230% Revenue Surge

CSPC Pharmaceutical Launches Phase 2 Trial of SYS 6026 mRNA Vaccine for HPV-Related Cervical Precancer

PegBio Launches Commercial Prescriptions for Paidakang GLP-1RA in China, Triggers Milestone Payments

Sino Biopharmaceutical Subsidiary Secures NMPA Approval for IM-101 Therapeutic Vaccine in Chronic Hepatitis B

OrbusNeich Enrolls First Patient in Pivotal Japanese Trial for Proprietary Drug-Coated Balloon

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

GSK Secures Early FDA Approval for Jideytro – ROS1 Inhibitor for Resistant Non-Small Cell Lung Cancer

Pfizer Secures FDA Priority Review for TALZENNA-XTANDI Combination in Earlier-Stage Prostate Cancer

Ribo Life Science Reports Positive Phase 2a Results for Vortosiran in Chronic Coronary Artery Disease

Haisco Pharma Secures NMPA Approval for HSK39297 – First Oral CFB Inhibitor for Paroxysmal Nocturnal Hemoglobinuria in China

Takeda Secures World’s First NMPA Approval for Orexatone – Novel Oral OX2R Agonist for Type 1 Narcolepsy

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Youcare Pharmaceutical Receives NMPA Approval for YKYY033 Clinical Trials Across Multiple Thrombotic Indications

Trinomab Biotechnology Debuts on Shanghai STAR Market with First-in-Class Anti-Tetanus Monoclonal Antibody

Novo Nordisk Sues Eli Lilly Over Alleged False Advertising of Zepbound and Mounjaro in GLP-1 Market

Junshi Biosciences Receives NMPA Acceptance for Toripalimab Expanded Indication in Resectable Stage II–III NSCLC

You Missed

Guangzhou Innogen’s Ultra-Long-Acting GLP-1 Agonist Efsubaglutide Alfa Advances to Adolescent Obesity Phase Ib Trial Following NMPA Approval for Diabetes

GSK Commits £400 Million to Establish Major Cambridge R&D Center, Consolidating UK Research Operations

Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients

Hansoh Pharmaceutical’s B7-H3 ADC Risvutatug Rezetecan Hits Primary Endpoint in Osteosarcoma Phase III Trial, Validating GSK Partnership